PharmaVoice

NOVEMBER 8, 2024

Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.

279

279

STAT

NOVEMBER 8, 2024

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We expect to continue the never-ending quest to manicure the Pharmalot grounds, promenade with the official mascots, and catch up on napping. We also hope to hold another listening party, where the rotation will likely include this , this , this , this and this.

FDA 108

FDA 108

Drug Topics

NOVEMBER 8, 2024

Joel Ferre, JD, Assistant United States Attorney in Utah, led a discussion covering the DEA and pharmacies’ roles in reporting red flags when dispensing medication.

Controlled Substances 247

Controlled Substances 247

STAT

NOVEMBER 8, 2024

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization.

141

141

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

NOVEMBER 8, 2024

A new study found that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.

Vaccines 190

Vaccines 190

Fierce Pharma

NOVEMBER 8, 2024

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to | Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate.

137

137

pharmaphorum

NOVEMBER 8, 2024

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities

137

137

Fierce Healthcare

NOVEMBER 8, 2024

The U.S. faces a critical shortage of primary care physicians, and the labor crunch is projected to get worse. | The company is working with New Mexico-based Presbyterian Healthcare Services to pilot its primary care AI pilot.

133

133

Pharmacy Times

NOVEMBER 8, 2024

Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.

Vaccines 132

Vaccines Hospitals 132

Pharmafile

NOVEMBER 8, 2024

BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of the most common type of bladder cancer, metastatic or unresectable urothelial carcinoma. The treatment, produced by Johnson & Johnson, will be a monotherapy for adults with bladder cancer. The decision by the MHRA was […] The post Johnson & Johnson receive MHRA approval for BALVERSA appeared first on Pharmafile.

59

59

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

NOVEMBER 8, 2024

The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that can cause scarring of the heart tissue.

FDA 131

FDA 131

Fierce Healthcare

NOVEMBER 8, 2024

LAS VEGAS — Employers' healthcare costs continue to rise, leading them to seek new alternatives to drive down expenses while avoiding steps to shift additional costs to workers. | In response to rising costs, some in the industry have been beating the drum for individual coverage health reimbursement arrangements, or ICHRA.

128

128

pharmaphorum

NOVEMBER 8, 2024

Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.

124

124

Pharmacy Times

NOVEMBER 8, 2024

Tripp Logan, PharmD, reflects on being named Independent Pharmacist of the Year from the National Community Pharmacists Association.

Independent Pharmacies 111

Independent Pharmacies 111

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

NOVEMBER 8, 2024

Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.

118

118

Pharmaceutical Technology

NOVEMBER 8, 2024

The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including Ozempic.

105

105

pharmaphorum

NOVEMBER 8, 2024

Conducting a cybersecurity audit on your pharmaceutical supply chain is crucial for protecting sensitive data. Learn how to properly assess and strengthen your cybersecurity measures with this guide.

109

109

Pharmaceutical Technology

NOVEMBER 8, 2024

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.

105

105

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

NOVEMBER 8, 2024

Explore the controversial issue of Testosterone Deficiency Syndrome (TDS) and the impact of America's testosterone paranoia with insightful analysis and perspectives on the topic.

105

105

Fierce Pharma

NOVEMBER 8, 2024

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and | The company opted not to renew its membership for 2025 following an annual review of its trade group associations, a spokesperson said.

99

99

pharmaphorum

NOVEMBER 8, 2024

Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.

105

105

Pharmaceutical Technology

NOVEMBER 8, 2024

Analysis of future trends highlights that the cold chain logistics sector is at a critical juncture, with tech advancements driving change.

98

98

pharmaphorum

NOVEMBER 8, 2024

Implementing cloud technology can help ensure the authenticity of pharmaceutical products like Ozempic, used for type 2 diabetes treatment. Learn how this technology is enhancing product security in the pharmaceutical industry generally.

105

105

Pharmaceutical Technology

NOVEMBER 8, 2024

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

96

96

Pharmacy Times

NOVEMBER 8, 2024

The demanding nature of pharmacy programs often leaves little time for self-care, social activities, or hobbies, leading to an imbalance that can foster burnout.

94

94

Fierce Pharma

NOVEMBER 8, 2024

Common oral medicines that have been used for decades as decongestants such as Sudafed, NyQuil and Benadryl may soon be cleared from shelves as the FDA has

FDA 90

FDA 90

Pharmacy Times

NOVEMBER 8, 2024

Off-label semaglutide has been linked to serious adverse effects, calling for increased regulation around compounding.

Compounding 94

Compounding Labelling Hospitals 94

pharmaphorum

NOVEMBER 8, 2024

The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances. That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health Data Research (HDR) UK – which found that accessing patient data can take months or even years, hampering research into areas like dementia, cancer and heart disease.

85

85

Pharmacy Times

NOVEMBER 8, 2024

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.

93

93

Fierce Pharma

NOVEMBER 8, 2024

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that AstraZeneca and Amgen's Tezspire provided a statistically significant and clinically meaningful reduction in polyp size and nasal congestion in patients with severe chronic rhinosinusitis with nasal polyps.

80

80

Outsourcing Pharma

NOVEMBER 8, 2024

Celebrating 35 years of innovation, Tjoapack has evolved into a leading force in pharmaceutical packaging.

Packaging 79

Packaging 79

Fierce Healthcare

NOVEMBER 8, 2024

Boulder Care, a telehealth addiction treatment company, is positioning itself to follow in the footsteps of major telehealth players like Livongo, Teladoc and Brightline. | Following a $35 million series C round in May, Boulder Care has invested in two new executive hires, Mitzi Yue and Meena Narayanan. Both come from top name digital health companies.

77

77

Fierce Pharma

NOVEMBER 8, 2024

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. | With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. Now, after several years spent validating its manufacturing platform, the company is expanding in a big way with the debut of a new service line and factory i

72

72